Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GD2L + GD3L + Globo H + fucosyl GM1 + N-propionylated polysialic acid + OPT-821
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This is a pentavalent cancer vaccine composed of keyhole limpet hemocyanin (KLH)-conjugates of five tumor-associated carbohydrate antigens (TACAs): GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid. The vaccine is designed to induce an immune response against multiple glycan antigens that are overexpressed on the surface of various cancer cells—particularly small cell lung cancer (SCLC) and other solid tumors. These glycolipids and glycoproteins play roles in tumor growth, metastasis, angiogenesis, and immune evasion. By targeting several antigens simultaneously with a polyvalent approach, the vaccine aims to overcome tumor heterogeneity and enhance complement-dependent cytotoxicity against cancer cells[1][2][9]. OPT-821 is an adjuvant used in this formulation to boost immunogenicity.
- Other names
- Polyvalent vaccine-KLH conjugate + OPT-821GD2L-KLH + GD3L-KLH + Globo H-KLH + fucosyl GM1-KLH + N-propionylated polysialic acid-KLH + OPT-821
02
Targets
GD2GD3 (Ganglioside GD3)Globo-HpolySia (Polysialic acid)Fuc-GM1 (Fucosyl-GM1 ganglioside)
Beyond the preview
Go deeper on GD2L + GD3L + Globo H + fucosyl GM1 + N-propionylated polysialic acid + OPT-821.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GD2L + GD3L + Globo H + fucosyl GM1 + N-propionylated polysialic acid + OPT-821.